Healsun Biopharm (Hangzhou Healsun Biopharm Co., Ltd.)

Hangzhou, China
Monoclonal Antibody Recombinant Protein Bispecific Antibody Fusion Protein ADC XDC (ADC, RDC, Bioconjugates) Cell Line Development (CHO)
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ○ Press ○ EMA GMP ○ MHRA GMP

Quick Facts: Healsun Biopharm (Hangzhou Healsun Biopharm Co., Ltd.)

Signal Score
60.0/100
Quality Compliance
Assessment pending
Headquarters
Hangzhou, China
Modalities
Monoclonal Antibody, Recombinant Protein, Bispecific Antibody, Fusion Protein, ADC, XDC (ADC, RDC, Bioconjugates), Cell Line Development (CHO)
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Healsun Biopharm (Hangzhou Healsun Biopharm Co., Ltd.)

Auto-created by AI matchmaker. Data verification pending.

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesMonoclonal Antibody, Recombinant Protein, Bispecific Antibody, Fusion Protein, ADC, XDC (ADC, RDC, Bioconjugates), Cell Line Development (CHO)
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 60.0
Broad modality coverage (7 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Broad modality coverage (7 modalities)

Frequently Asked Questions About Healsun Biopharm (Hangzhou Healsun Biopharm Co., Ltd.)

What is Healsun Biopharm (Hangzhou Healsun Biopharm Co., Ltd.)'s CDMO Signal Score?
Healsun Biopharm (Hangzhou Healsun Biopharm Co., Ltd.) has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating Healsun Biopharm (Hangzhou Healsun Biopharm Co., Ltd.) for a manufacturing program?
Use the free AI matchmaker to compare Healsun Biopharm (Hangzhou Healsun Biopharm Co., Ltd.) against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Recombinant Protein CDMOs → ADC CDMOs → XDC (ADC, RDC, Bioconjugates) CDMOs →

Similar CDMOs

AsymBio
Shanghai, China
Monoclonal Antibody, Bispecific Antibody, Recombinant Protein, ADC, Bioconjugates (NDC, RDC, AOC, PDC, BsADC), Plasmid DNA, mRNA, Fill-Finish
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Signal Score: 80.6
CAR-T, Cell Therapy, AAV, Lentiviral, ADC, Monoclonal Antibody, Recombinant Protein
Lonza
Basel, Switzerland
Signal Score: 78.2
AAV, Lentiviral, Cell Therapy, mRNA, ADC, Monoclonal Antibody, Recombinant Protein
Catalent
Bagsværd, Denmark (Bloomington, IN primary fill-finish site; operating under Novo Holdings)
Signal Score: 76.5
Monoclonal Antibody, Recombinant Protein, ADC, AAV, mRNA, Plasmid DNA, Fill-Finish
Catalent (Novo Holdings)
Harmans, MD · Gosselies, BE
Signal Score: 75.1
Monoclonal Antibody, Recombinant Protein, ADC, AAV, mRNA, Plasmid DNA, Fill-Finish